Buscar
Mostrando ítems 1-5 de 5
Cytogenetic effect of 5-azacytidine in patients with hematological malignancies
(Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular, 2011-10-01)
BACKGROUND: Recently, the importance of cytogenetics has grown in the diagnosis, prognosis and treatment of leukemias and myelodysplastic syndromes. 5-azacytidine is a drug that has well-known cytogenetical effects and is ...
Chromosome damage induced by 5-azacytidine under the influence of caffeine or cytosine arabinoside in CHO-K1 (wild-type) and XRS-5 (mutant) cell lines
(2001-07-14)
5-azacytidine (5-azaC) treatment combined with cytosine arabinoside (ara-C) or caffeine were performed in vitro in Chinese hamster cells, CHO-K1 (wild-type) and xrs-5 (mutant) cell lines, in order to compare the cell ...
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
(Nature Publishing GroupLondonInglaterra, 2014)
Accesibilidad de herramientas diagnóstico- terapéuticas para los pacientes con síndromes mielodisplásicos en la República ArgentinaAccess to diagnostic and therapeutic tools for myelodysplastic syndromes in Argentina
(Sociedad Argentina de Hematologia, 2017-05)
Los síndromes mielodisplásicos (SMD) constituyen un grupo heterogéneo de enfermedades hematológicas clonales cuya confirmación diagnóstica requierede un equipo interdisciplinario para la evaluación clínica, la descripción ...
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer
(Nature Publishing Group, 2017-12)
Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise ...